Neuroscience
A novel approach to neurology could bring relief to people in pain
In August 2020, V-Bio Ventures announced their investment in Biodol Therapeutics, a French start-up looking to make a difference to […] August 31, 2020 · V-Bio Ventures
Decades-old discoveries cause paradigm shifts in modern medicine
Complete paradigm shifts in medicine are rare, but there have nevertheless been several major examples in the past hundred years. […] December 16, 2020 · V-Bio Ventures
Prestigious prize for Belgian breakthrough in brain research
Prof. Dr. Pierre Vanderhaeghen from VIB-KU Leuven has been awarded the Generet Prize for Rare Diseases for his research on […] January 27, 2021 · BioVoxAugustine Therapeutics appoints Sylvain Celanire as CEO to accelerate development of innovative medicines for rare neuromuscular diseases
Leuven, Belgium, 18th March 2021 – Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare […] March 18, 2021 · Turnstone CommunicationsAugustine Therapeutics strengthens Board of Directors and sets up Scientific Advisory Board
Leuven, Belgium, 19th March 2021 – Augustine Therapeutics, a biotech company focused on the development of innovative medicines for rare […] March 19, 2021 · Turnstone CommunicationsAugustine Therapeutics awarded EUR 1.2 million VLAIO research grant to develop new medicines for neuromuscular diseases
Leuven, Belgium, 23 March 2021 – Augustine Therapeutics, a biotech spin-out company from VIB that focuses on the development of […] March 23, 2021 · Turnstone Communications
Augustine Therapeutics developing new medicines for neuromuscular diseases
Augustine Therapeutics had a lot of announcements this month: the VIB spin-off just appointed Dr. Sylvain Celanire as CEO, strengthened […] March 31, 2021 · Turnstone Communications
To fund or not to fund: the psychology of investment decisions
Much has been written about the psychology of decision making and how venture capitalists choose which companies they want to […] April 28, 2021 · V-Bio VenturesNewton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy
– Newton together with public and private investment partners invests in NeuVasQ for the development of blood-brain barrier pharmaceuticals based […] June 22, 2021 · Turnstone Communications
Biogen’s controversial Alzheimer’s drug approved by the FDA – what now?
It has been three months since the much-discussed FDA approval of Biogen’s Aduhelm, a treatment for Alzheimer’s Disease. The drug […] September 22, 2021 · V-Bio Ventures
Confo-dently into the future!
Confo Therapeutics is a rising star in Belgium, featured on several local and international lists of up-and-coming biotechs. The company, […] November 24, 2021 · V-Bio VenturesV-Bio Ventures’ Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio
Ghent, Belgium, 1 March 2022 – V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi […] March 1, 2022 · V-Bio Ventures